Haematologisch Onkologische Praxis Eppendorf / Norddeutsches Studienzentrum für Innovative Onkologie — Clinical Trial Site

9 Registered trials

3 Currently recruiting

Organisation

Haematologisch Onkologische Praxis Eppendorf / Norddeutsches Studienzentrum für Innovative Onkologie

Location

Hamburg, Germany

Identifier

ORL-000001505

Address

Eppendorfer Landstrasse 42, 20249, Germany

Departments

Hämatologisch Onkologische Praxis Eppendorf
Hämatologisch-Onkologische Praxis Eppendorf (Hope)
N/A
NA
Norddeutsches Studienzentrum für Innovative Onkologie
Norddeutsches Studienzentrum für Innovative Onkologie (NIO)
Oncology

Clinical trials at this site (9)

Search interface

A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cance… Pending

2024-519787-40-00 Gastric Cancer, Gastroesophageal Junction Adenocarcinom 5
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Unresectable, Locally Advanced or Metastatic HER2 posit 5 2025-06-10
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
A study to test if different doses of D3S-001 used on its own or in combination with other anti-cancer medicines is safe and tolerable in pe… Recruiting

2023-508517-16-00 Advanced Solid Tumors with a KRAS p.G12C Mutation 7 2024-11-10
NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therap… Halted

2024-518841-12-00 HER2 positive resectable esophagogastric adenocarcinoma 9 2025-03-25
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Adv… Ended

2022-501465-40-00 Colorectal Cancer 4 2023-12-22
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First Line or Second-Line Therapy in A… Ended

2023-504940-32-00 Gastric cancer 4 2023-10-13
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 Gastric and Gastroesophageal Junction Cancer With FGFR2 5 2022-09-13
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04